NEW YORK (GenomeWeb News) — Merck has closed its $1.1-billion cash acquisition of Sirna Therapeutics, Merck said last week.
 
Merck originally announced its plan to acquire the RNAi company on Oct. 30, 2006, but waited for regulatory approval and for Sirna shareholders to give the nod, which they did on Dec. 28, 2006.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.